Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease

OpenMIND

A major challenge facing Europe is its ageing population and associated increase in diagnosed cases of neurodegenerative diseases (NDD). Parkinson’s disease (PD) is associated with tremor and loss of motor functions due to progressive degeneration of dopaminergic neurons in the brain. This can lead to memory loss and dementia, which is associated...

Funding Programme
Start Date
End Date
Total Funding
€ 2 992 203
European Countries Involved

Patient-specific stem cell-derived models for Alzheimer’s disease and related neurodegenerative disorders

STEMMAD

Future treatment of incurable neurodegenerative disorders, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), spinocerebellar ataxia (SCA), and Huntington’s disease (HD), has to be tailored to individual patients or cohorts of patients to obtain an optimal effect. The STEMMAD project is aimed to create a highly innovative...

Funding Programme
Start Date
End Date
Total Funding
€ 2 782 410
European Countries Involved

Peripheral Biomarker Based Combinatorial Early Diagnostics for Dementia

CombiDiag

CombiDiag DN aims to develop an AI-data-driven peripheral biomarker based combinatorial diagnostic protocol for early stages of Alzheimers disease (AD), a major form of dementia, and to train a new generation of fellows for this interdisciplinary field. Dementia, a devastating disease of older age, is the challenge of our lifetime and one of the...

Funding Programme
Start Date
End Date
Total Funding
€ 2 160 201
European Countries Involved

PRE-CLINICAL GENOTYPE-PHENOTYPE PREDICTORS OF ALZHEIMER’S DISEASE AND OTHER DEMENTIA

APGeM

Alzheimer’s disease, Lewy-body dementias (including Parkinson’s disease) and other neurodegenerative dementias are major causes of disease, reduced patient- and caregiver quality of life, and increasing societal health costs. All have lengthy (decades) pre-dementia- and pre-clinical stages, but patients will have suffered irreversible brain damage...

Funding Programme
Start Date
End Date
Total Funding
€ 1 730 000
European Countries Involved

Precision Medicine Interventions in Alzheimer’s Disease

PMI-AD

Alzheimer’s disease (AD) is characterized by brain nerve cell death and dementia, but before dementia, leading up to these final and irreversible end-points we first see loss of synapses, which are the contacts between nerve cells allowing us to think, learn and function as independent beings. Coincident with early synaptic loss we also see...

Funding Programme
Start Date
End Date
Total Funding
€ 2 000 000
European Countries Involved

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

PREDICTOM

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care...

Funding Programme
Start Date
End Date
Total Funding
€ 8 449 326

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development

PHARMA-COG

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug candidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmacological challenges, Phase 0/1/1b to reduce the attrition rate...

Funding Programme
Start Date
End Date
Total Funding
€ 30 499 556

Prevention and Remediation of Insulin Multimorbidity in Europe

PRIME

PRIME introduces the novel concept of insulin signalling as a key mechanism underlying the multimorbidity of major mental and somatic illnesses. It is well known that aberrant insulin signalling causes high health and socioeconomic burden through its role in diabetes, metabolic syndrome, and obesity. We posit that the impact of ‘insulinopathies’ is...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 001
European Countries Involved

Proteomics of neuroinflammatory signaling: Illuminating cellular mechanisms driving neurodegenerative diseases

NEUROINFLAM-MS

Alzheimers (AD) and Parkinsons disease (PD) are prevalent neurodegenerative diseases, but their underlying mechanisms remain poorly understood. Emerging evidence suggests that neuroinflammation, characterized by the release of pro-inflammatory cytokines like IL-1, TNF-, and INF-, plays a pivotal role in these diseases, challenging the conventional...

Funding Programme
Start Date
End Date
Total Funding
€ 230 774
European Countries Involved

Real world outcomes across the AD spectrum for better care: multi-modal data access platform

ROADMAP

Alzheimer’s disease is on the rise in our ageing population, and new, effective treatments are urgently needed. Currently, the safety and benefits to patients of potential treatments are assessed in strictly-controlled clinical trials. However, clinical trials do not provide information on the health benefits for patients in their daily lives in...

Funding Programme
Start Date
End Date
Total Funding
€ 8 210 381
European Countries Involved

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

RECOGNISED

In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with dramatic consequences for patients and their families and a significant impact for healthcare systems. At present there are no reported...

Funding Programme
Start Date
End Date
Total Funding
€ 5 998 273

Risk and Modifying factors in Fronto Temporal Dementia

RiMod-FTD

Fronto-Temporal-Dementia (FTD) is a devastating progressive early onset dementia with a strong genetic influence. Currently, seven genes have been identified that explain >50% of familial cases, but how these different genes lead to a very similar clinical phenotype is still an unanswered question. Currently, there is no cure for FTD and for the...

Funding Programme
Start Date
End Date
Total Funding
€ 3 190 796
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).